PP
NYMX

Paloma Partners’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Paloma Partners’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,154
Closed -$31K – 2286
2020
Q1 		$31K Buy
+13,154
New +$36.9K ﹤0.01% 1137

Other funds holding NYMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Paloma Partners's NYMX Position: Q2 2020 in Review

Paloma Partners sold out of Nymox Pharmaceutical Corp (NYMX) in Q2 2020, closing a stake of 13,154 shares — an estimated $31K sold.

Paloma Partners first reported a position in NYMX in Q1 2020 and held it in 1 quarter. The position peaked at $31K in Q1 2020. 63 funds tracked by Wall St. Rank hold NYMX as of Q2 2020.

  • Paloma Partners reported no remaining Nymox Pharmaceutical Corp position as of Q2 2020 after selling out during the quarter.
  • Paloma Partners sold 13,154 Nymox Pharmaceutical Corp shares in Q2 2020, an estimated $31K.
  • Paloma Partners first reported a position in Nymox Pharmaceutical Corp in Q1 2020 and held it in 1 quarter.
  • Paloma Partners's Nymox Pharmaceutical Corp position peaked at $31K in Q1 2020.
  • 63 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q2 2020.

Based on Paloma Partners's 13F filing for Q2 2020, filed 14 Aug 2020.